Cephalon, Inc. Harvard Case Solution & Analysis

Cephalon, Inc. Case Solution

In early 1997, Cephalon, awaited an FDA panel's conclusion on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might want considerable additional funds to commercialize and to purchase the rights again.
The CFO of the firm is contemplating various funding strategies, including paying for those options by issuing shares at the present time and purchasing call options on the firm's own stock.

This is just an excerpt. This case is about  FINANCE & ACCOUNTING

PUBLICATION DATE: April 13, 1998

Cephalon, Inc. Case Solution Other Similar Case Solutions like

Cephalon, Inc.

Share This